Ira J Dunkel

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina, and Department of Pathology, University of Sao Paulo, Brazil
    Pediatr Blood Cancer 49:256-60. 2007
  2. ncbi request reprint High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
    I J Dunkel
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:222-8. 1998
  3. doi request reprint Trilateral retinoblastoma: potentially curable with intensive chemotherapy
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Pediatr Blood Cancer 54:384-7. 2010
  4. ncbi request reprint A phase II trial of carboplatin for intraocular retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 49:643-8. 2007
  5. pmc High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, Box 185, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 12:297-303. 2010
  6. doi request reprint Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 55:55-9. 2010
  7. doi request reprint High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 55:149-52. 2010
  8. ncbi request reprint High-dose chemotherapy with autologous stem cell rescue for brain tumors
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, Department of Pediatrics, Box 185, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 41:197-204. 2002
  9. ncbi request reprint Successful treatment of metastatic retinoblastoma
    I J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 89:2117-21. 2000
  10. pmc Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group
    Jonathan L Finlay
    The Children s Center for Cancer and Blood Diseases, Department of Pediatrics, Children s Hospital, Los Angeles, California 90027, USA
    Pediatr Blood Cancer 51:806-11. 2008

Detail Information

Publications78

  1. ncbi request reprint Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma
    Guillermo L Chantada
    Department of Hemato Oncology, Hospital JP Garrahan, Buenos Aires, Argentina, and Department of Pathology, University of Sao Paulo, Brazil
    Pediatr Blood Cancer 49:256-60. 2007
    ..To assess the outcome and determine risk factors for extraocular relapse in patients with retinoblastoma who had been enucleated after failure of chemoreduction...
  2. ncbi request reprint High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
    I J Dunkel
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:222-8. 1998
    ..Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma...
  3. doi request reprint Trilateral retinoblastoma: potentially curable with intensive chemotherapy
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Pediatr Blood Cancer 54:384-7. 2010
    ..We describe a series of 13 patients treated with intensive chemotherapy, defined as the intention to include high-dose chemotherapy with autologous hematopoietic stem cell rescue...
  4. ncbi request reprint A phase II trial of carboplatin for intraocular retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 49:643-8. 2007
    ....
  5. pmc High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, Box 185, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 12:297-303. 2010
    ..09). This retrieval strategy provides long-term EFS for some patients with previously irradiated recurrent medulloblastoma. The use of additional RT may be associated with better outcome...
  6. doi request reprint Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 55:55-9. 2010
    ....
  7. doi request reprint High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 55:149-52. 2010
    ..Here we describe a series of eight patients treated with intensive chemotherapy, defined as the intention to include high-dose chemotherapy with autologous hematopoietic stem cell rescue...
  8. ncbi request reprint High-dose chemotherapy with autologous stem cell rescue for brain tumors
    Ira J Dunkel
    Memorial Sloan Kettering Cancer Center, Department of Pediatrics, Box 185, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 41:197-204. 2002
    ..The role of this treatment strategy for other chemotherapy-sensitive tumors such as oligodendrogliomas and central nervous system germ cell tumors has yet to be determined...
  9. ncbi request reprint Successful treatment of metastatic retinoblastoma
    I J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 89:2117-21. 2000
    ..In the current study, the authors evaluated the use of combined intensive conventional chemotherapy, high dose chemotherapy with autologous stem cell rescue (ASCR), and radiation therapy...
  10. pmc Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group
    Jonathan L Finlay
    The Children s Center for Cancer and Blood Diseases, Department of Pediatrics, Children s Hospital, Los Angeles, California 90027, USA
    Pediatr Blood Cancer 51:806-11. 2008
    ..Children and adolescents with malignant astrocytomas recurring after initial treatment have a dismal prognosis, with only rare patients surviving 1-year beyond recurrence. The purpose of this study was to attempt to improve their survival...
  11. ncbi request reprint Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue
    Jason R Fangusaro
    The Children s Hospital Los Angeles, New York University Medical Center, Memorial Sloan Kettering Cancer Center, and Schneider Children s Hospital, USA
    Pediatr Blood Cancer 50:715-7. 2008
    ..Two patients survive at least 32 months with stable disease. This approach provides an alternative for young patients with bstPNET who in prior reports have had a uniformly fatal prognosis...
  12. doi request reprint Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery)
    David H Abramson
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ophthalmology 117:1623-9. 2010
    ..To report on our 3-year experience with the use of superselective ophthalmic artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma...
  13. ncbi request reprint Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue
    John A Heath
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 24:160-3. 2002
    ..It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue...
  14. doi request reprint ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma
    Scott E Brodie
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Br J Ophthalmol 96:877-80. 2012
    ..In this paper, we report ERG results for patients with retinoblastoma receiving initial treatment with systemic chemotherapy...
  15. doi request reprint Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma
    Scott E Brodie
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Doc Ophthalmol 119:13-22. 2009
    ..To assess potential retinal viability by electroretinography following selective ophthalmic artery chemotherapy infusion for retinoblastoma...
  16. doi request reprint Subarachnoid dissemination of intraventricular tumors following simultaneous endoscopic biopsy and third ventriculostomy
    Neal Luther
    Department of Neurological Surgery, Weill Cornell Medical College, New York, New York 10021, USA
    J Neurosurg Pediatr 5:61-7. 2010
    ..The aim of this study was to ascertain the rate of leptomeningeal dissemination following this surgical procedure...
  17. ncbi request reprint Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results
    Brian P Marr
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Ophthalmol 96:1300-3. 2012
    ..To report outcomes with selective intra-arterial chemotherapy (SIAC) using simultaneous carboplatin, topotecan, and melphalan for advanced intraocular retinoblastoma...
  18. doi request reprint Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy
    Brian P Marr
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Ophthalmol 130:180-5. 2012
    ....
  19. ncbi request reprint High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors
    Alberto Broniscer
    Children s Cancer Group New York University Medical Center, New York, NY, USA
    Pediatr Blood Cancer 42:261-7. 2004
    ..XSWe tested the efficacy of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in this setting...
  20. doi request reprint The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors
    Aerang Kim
    New York University Medical Center, New York, New York, USA
    Pediatr Blood Cancer 51:768-73. 2008
    ....
  21. ncbi request reprint Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1934-43. 2004
    ..To evaluate the efficacy and toxicity of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in patients with relapsed or progressive CNS germ cell tumors (GCTs)...
  22. doi request reprint Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma
    William R Polkinghorn
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 81:e15-20. 2011
    ..In order to decrease ototoxicity, we subsequently implemented a tumor-bed boost using intensity-modulated radiation therapy (IMRT), the clinical results of which we report here...
  23. doi request reprint Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system
    Stephen W Gilheeney
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 54:591-5. 2010
    ..We present ten patients with recurrent or progressive central nervous system malignancies treated on a myeloablative regimen using these drugs...
  24. doi request reprint Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Danielle Novetsky Friedman
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 60:694-9. 2013
    ..Data on long-term outcomes of survivors of extra-ocular retinoblastoma are lacking. The authors sought to provide the first report characterizing long-term outcomes among survivors of extra-ocular retinoblastoma...
  25. doi request reprint Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results
    David H Abramson
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Br J Ophthalmol 96:499-502. 2012
    ..To review the effectiveness of intra-arterial chemotherapy for advanced intra-ocular retinoblastoma with vitreous and/or subretinal seeds in naive (untreated) and previously treated eyes...
  26. doi request reprint Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience
    Y Pierre Gobin
    Interventional Neuroradiology, Departments of Radiology and Neurosurgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10065, USA
    Arch Ophthalmol 129:732-7. 2011
    ..Retinoblastoma often presents with advanced intraocular disease and, despite conventional treatment with intravenous chemotherapy and external beam radiation therapy, may still require enucleation...
  27. doi request reprint Ophthalmic artery chemosurgery for retinoblastoma prevents new intraocular tumors
    David H Abramson
    Department of Ophthalmology at Weill Cornell Medical School, New York, New York, USA
    Ophthalmology 120:560-5. 2013
    ..To determine the incidence and timing of new intraocular tumor foci in genetic retinoblastoma cases after treatment with ophthalmic artery chemosurgery (OAC)...
  28. doi request reprint Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment
    Sotiria Palioura
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 59:859-64. 2012
    ..e. ophthalmic artery chemosurgery, has been used for the treatment of advanced intraocular retinoblastoma. Herein, we evaluate the efficacy of ophthalmic artery chemosurgery for retinoblastoma associated with >50% retinal detachment...
  29. doi request reprint Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity
    Brian P Marr
    Department of Surgery, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, 70 East 66th Street, New York, NY 10065, USA
    Br J Ophthalmol 96:881-3. 2012
    ..To report the experience of the authors with efficacy and toxicity of periocular chemotherapy over a 12-year period...
  30. ncbi request reprint Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma
    David H Abramson
    Department of Ophthalmology, New York Presbyterian Hospital Weill Medical College of Cornell University, 70 E 66th Street, New York, NY 10021, USA
    Arch Ophthalmol 122:1316-23. 2004
    ..To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth group Vb retinoblastoma...
  31. ncbi request reprint Primary leptomeningeal primitive neuroectodermal tumor
    Martin Begemann
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 63:299-303. 2003
    ..After the initial presentation of 3.5 years the boy began to suffer from prolonged refractory non-convulsive status epilepticus and later expired from progression of primary leptomeningeal PNET...
  32. ncbi request reprint Preliminary results of dose intensive pre-irradiation chemotherapy in patients older than 10 years of age with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors
    Kavita Dhodapkar
    New York University Medical Center, New York, NY, USA
    Med Pediatr Oncol 38:47-8. 2002
  33. doi request reprint Intra-arterial and oral digoxin therapy for retinoblastoma
    Mrinali Patel
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
    Ophthalmic Genet 32:147-50. 2011
    ..Preclinical studies demonstrate that cardiac glycosides such as ouabain and digoxin have antitumor effects on retinoblastoma cells in vitro and in a xenograft murine model of retinoblastoma...
  34. ncbi request reprint Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10021, USA
    J Clin Oncol 21:3079-83. 2003
    ..To assess the patterns of failure for patients with medulloblastoma receiving a conformal tumor bed boost rather than a boost to the entire posterior fossa...
  35. pmc Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma
    Y Pierre Gobin
    Service of Interventional Neuroradiology, Department of Neurosurgery, Weill Cornell Medical College of New York Presbyterian Hospital, New York, New York, United States of America
    PLoS ONE 7:e44322. 2012
    ..a.) chemotherapy has more risks of procedural complications in neonates and young infants. For these reasons, we have developed a strategy of bridge intravenous single agent chemotherapy to postpone i.a. chemotherapy in these children..
  36. doi request reprint Reirradiation for recurrent medulloblastoma
    Richard L Bakst
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:4977-82. 2011
    ..Reirradiation is often not considered secondary to its potential toxicity and uncertain efficacy. Analysis of retreatment could help identify the feasibility and role of reirradiation for recurrent MB...
  37. ncbi request reprint New retinoblastoma tumor formation in children initially treated with systemic carboplatin
    Thomas C Lee
    Department of Ophthalmology, New York Presbyterian Hospital Weill Medical College of Cornell University, 70 East 66th Street, New York, NY 10021, USA
    Ophthalmology 110:1989-94; discussion 1994-5. 2003
    ..To determine the frequency and timing of new intraocular tumor formation in children with hereditary retinoblastoma initially treated with systemic carboplatin...
  38. ncbi request reprint Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors
    S Guruangan
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:2486-93. 1998
    ....
  39. ncbi request reprint Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5465-70. 2007
    ..We tested the toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a phase I clinical trial...
  40. ncbi request reprint Current management strategies for intraocular retinoblastoma
    Jonathan W Kim
    Department of Ophthalmic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Drugs 67:2173-85. 2007
    ..Therefore, modern centres treating retinoblastoma continue to manage patients with a variety of modalities, individualising the therapy according to the patient's presentation and clinical course...
  41. ncbi request reprint Lack of activity of oral etoposide for relapsed intraocular retinoblastoma
    Ira J Dunkel
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ophthalmic Genet 25:25-9. 2004
    ..Because oral etoposide has been found to be highly effective in patients with relapsed medulloblastoma and neuroblastoma who had previously received intravenous etoposide, we investigated its use for intraocular retinoblastoma...
  42. doi request reprint Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies--an analysis of impact
    Danielle E Novetsky
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ophthalmic Genet 30:40-4. 2009
    ..To determine the impact of subtle differences (most notably in their classification of group E eyes) in two published versions of the ICRB (Philadelphia and the Children's Hospital Los Angeles)...
  43. doi request reprint Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9
    Neal Luther
    Department of Neurological Surgery, Weill Cornell Medical College, New York, New York 10021, USA
    Neurosurgery 63:1166-74; discussion 1174. 2008
    ..Interstitial delivery of murine immunoglobulin G1 monoclonal antibody (MAb) 8H9 was investigated in a rodent model for the potential treatment of infiltrative gliomas...
  44. doi request reprint Novel use of zolpidem in cerebellar mutism syndrome
    Charles Shyu
    Department of Neurology, University of Illinois at Urban Champaign, New York, NY 10065, USA
    J Pediatr Hematol Oncol 33:148-9. 2011
    ..Our report suggests that clinicians should consider using zolpidem for patients with CMS...
  45. pmc Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma
    Jasmine H Francis
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e72441. 2013
    ..We aimed to assess the efficacy and toxicity of carboplatin +/- topotecan delivered by ophthalmic artery chemosurgery whereby chemotherapy is infused into the eye via the ophthalmic artery...
  46. pmc Intraocular hemorrhage after intra-arterial chemotherapy for retinoblastoma in sickle cell trait
    David H Abramson
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
    Open Ophthalmol J 6:1-3. 2012
    ..Clinicians should be on the lookout for the association of sickle-cell disease/trait and intraocular hemorrhages after intraarterial chemotherapy to fully understand its clinical significance...
  47. doi request reprint Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors
    Mark M Souweidane
    Department of Neurological Surgery, Weill Cornell Medical College, and Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neurosurgery 65:72-8; discussion 78. 2009
    ..This study was conducted to determine whether arachnoid tissue or cerebrospinal fluid (CSF) sampling is valuable for risk stratification in children with posterior fossa brain tumors...
  48. doi request reprint A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results
    David H Abramson
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ophthalmology 115:1398-404, 1404.e1. 2008
    ....
  49. ncbi request reprint Impairments in antifolate transport are common in retinoblastoma tumor samples
    Richard G Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:573-6. 2008
    ..Identification of effective chemotherapy agents for retinoblastoma that are not associated with an elevated risk of secondary malignancy would be beneficial...
  50. ncbi request reprint Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults
    B H Kushner
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Bone Marrow Transplant 28:551-6. 2001
    ....
  51. doi request reprint Quality of life and behavioral follow-up study of Head Start I pediatric brain tumor survivors
    Stephen A Sands
    Departments of Pediatrics and Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Neurooncol 101:287-95. 2011
    ....
  52. doi request reprint Sinonasal adenocarcinoma: a rare second malignancy in long term retinoblastoma survivors
    Pooja Bhagia
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 57:693-5. 2011
    ..Sinonasal adenocarcinoma should be considered as a second malignancy in retinoblastoma survivors who present with vague sinus symptoms...
  53. ncbi request reprint Correlation of endoscopic biopsy with tumor marker status in primary intracranial germ cell tumors
    Neal Luther
    Department of Neurological Surgery, Weill Medical College of Cornell University, New York, NY, USA
    J Neurooncol 79:45-50. 2006
    ..We would thus conclude that when primary germ cell tumor is considered, endoscopic tumor biopsy is recommended in patients with a negative biochemical analysis, but not suggested for patients presenting with elevated tumor markers...
  54. ncbi request reprint A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies
    Stephen W Gilheeney
    Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 49:261-5. 2007
    ..This trial was undertaken to investigate whether the combination of cyclophosphamide and thalidomide would be active against pediatric tumors...
  55. ncbi request reprint More aggressive bone marrow screening in retinoblastoma patients is not indicated: the memorial Sloan-Kettering cancer center experience
    Stergios Zacharoulis
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 46:56-61. 2006
    ....
  56. ncbi request reprint Sclerosing epithelioid fibrosarcomas involving the neuraxis: report of three cases
    M H Bilsky
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Neurosurgery 47:956-9; discussion 959-60. 2000
    ..A single instance of brain and vertebral metastasis has been described. We report three examples of SEF distinguished by primary involvement of the neuraxis at initial presentation...
  57. ncbi request reprint Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8
    K Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:716-8. 2000
    ..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
  58. ncbi request reprint Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences
    Linda J Butros
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatrics 109:E45. 2002
    ..To assess the degree, cause, and consequence of delays from presenting signs to diagnosis of retinoblastoma...
  59. ncbi request reprint Recurrent ependymoma treated with high-dose tamoxifen in a peripubertal female: Impact on tumor and the pituitary-ovarian axis
    Rona Yoffe
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 49:758-60. 2007
    ..However, treatment with tamoxifen resulted in the development of large ovarian cysts associated with supraphysiological plasma concentrations of estradiol...
  60. doi request reprint Intraventricular meningioma after cranial irradiation for childhood leukemia
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Child Neurol 25:1292-5. 2010
    ..Radiation-induced meningiomas may also have predilection to recur. The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic leukemia...
  61. pmc Systemic carboplatin for retinoblastoma: change in tumour size over time
    D H Abramson
    70 East 66th Street, New York, NY 10021, USA
    Br J Ophthalmol 89:1616-9. 2005
    ..Quantitative data regarding retinal tumour response following treatment with primary systemic carboplatin are reported...
  62. doi request reprint Diffusion-weighted imaging to assess treatment response in a child with trilateral retinoblastoma
    Gregory A Bonci
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Pediatr Radiol 43:1231-4. 2013
    ..We highlight a case where close evaluation of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) characteristics accurately depicted the extent of treated disease versus residual tumor after chemotherapy. ..
  63. pmc Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma
    Brian Marr
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Middle East Afr J Ophthalmol 17:207-9. 2010
    ..To describe an unusual clinical finding seen in children undergoing intra-arterial chemotherapy for retinoblastoma...
  64. ncbi request reprint Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine
    Mark M Souweidane
    Department of Neurological Surgery, The Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 67:319-26. 2004
    ....
  65. doi request reprint Vancomycin-resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection
    Amanda Kosack
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 52:300-2. 2009
    ..None of the hypothesized risk factors appeared to differ between patients who developed a subsequent infection and those who did not...
  66. pmc Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma
    Carolyn P Graeber
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Open Ophthalmol J 5:1-5. 2011
    ..MATERIALS AND METHODOLOGY: Independent histopathologic review of the enucleated eyes was correlated with the clinical findings that prompted enucleation...
  67. doi request reprint Orbital recurrence of retinoblastoma following enucleation
    J W Kim
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Br J Ophthalmol 93:463-7. 2009
    ..To determine the incidence, clinical presentation and histopathological profile of patients developing orbital recurrence following enucleation for retinoblastoma...
  68. pmc Characteristics of oral mucosal events related to bevacizumab treatment
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Oncologist 17:274-8. 2012
    ..We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab...
  69. ncbi request reprint Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice
    Y Yan
    Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur J Cancer 36:221-8. 2000
    ..c. inoculation and suggest the possibility of using the SCID mouse model to study the intrinsic biological behaviour of human retinoblastoma and to develop novel therapeutic strategies in the treatment of this disease...
  70. ncbi request reprint Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma
    D H Abramson
    Department of Ophthalmology, New York-Presbyterian Hospital, New York Weill Cornell Medical Center, New York, New York, USA
    Ophthalmology 108:1868-76. 2001
    ..The locations and expected ages at which additional tumors develop are consistent with the patterns we have seen in second tumors...
  71. ncbi request reprint Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach
    Stewart J Kellie
    Oncology Unit, The Children s Hospital at Westmead, Sydney, NSW, Australia
    Pediatr Blood Cancer 43:126-33. 2004
    ..The primary objective of this study was to determine whether intensive cisplatin and cyclophosphamide-based combination chemotherapy, without radiotherapy, was effective in patients with CNS germinomas...
  72. ncbi request reprint The adverse events of chemotherapy for retinoblastoma: what are they? Do we know?
    Allison E Rizzuti
    Arch Ophthalmol 126:862-5. 2008
  73. ncbi request reprint Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol
    Stewart J Kellie
    Oncology Unit, The Children s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia
    J Clin Oncol 22:846-53. 2004
    ..The primary objective of this study was to determine whether intensive cisplatin and cyclophosphamide-based combination chemotherapy was effective in patients with intracranial NGGCT...
  74. doi request reprint Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols
    Girish Dhall
    Childrens Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:1169-75. 2008
    ..To determine the survival of infants and young children with non-metastatic medulloblastoma using intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)...
  75. ncbi request reprint A proposal for an international retinoblastoma staging system
    Guillermo Chantada
    Department of Hematology Oncology, Hospital JP Garrahan, Buenos Aires, Argentina
    Pediatr Blood Cancer 47:801-5. 2006
    ..Comparisons among studies that consider disease extension, risk factors for extra-ocular relapse, and response to therapy require a universally accepted staging system for extra-ocular disease...
  76. ncbi request reprint Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?
    Dan S Gombos
    Section of Ophthalmology, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ophthalmology 114:1378-83. 2007
    ..To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB)...
  77. ncbi request reprint Treatment-related myelodysplastic syndrome after chemotherapy for childhood low-grade astrocytoma
    Matthias A Karajannis
    J Pediatr Hematol Oncol 28:700. 2006
  78. ncbi request reprint Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine
    Girish Dhall
    Children s Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:72-9. 2008
    ..To assess the activity and tolerability of 2-chlorodeoxyadenosine (2-CDA) in treating mass lesions of the central nervous system (CNS) due to Langerhans cell histiocytosis (LCH)...